Recent News

• 05.26.2026 - BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
• 05.26.2026 - BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
• 05.13.2026 - BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
• 05.13.2026 - BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
• 05.07.2026 - BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
• 05.07.2026 - BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
• 04.30.2026 - BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
• 04.30.2026 - BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
• 04.21.2026 - BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform
• 04.07.2026 - BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

Recent Filings

• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.01.2026 - 8-K Current report
• 04.30.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.28.2026 - EFFECT Notice of Effectiveness
• 04.27.2026 - POS AM Post-Effective amendments for registration statement
• 04.23.2026 - 8-K Current report
• 04.23.2026 - EX-99.1 EX-99.1
• 04.20.2026 - POS AM Post-Effective amendments for registration statement
• 04.13.2026 - DEF 14A Other definitive proxy statements